NAV5001

DRUG2 trials

Sponsors

Navidea Biopharmaceuticals

Conditions

Parkinson's Syndrome

Phase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

TerminatedNCT01950455

Navidea BiopharmaceuticalsParkinson's Syndrome

Start: 2013-11-30End: 2018-01-31Updated: 2018-10-05

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

WithdrawnNCT01950468

Navidea BiopharmaceuticalsParkinson's Syndrome

Start: 2017-04-30End: 2018-03-31Updated: 2017-09-13